Alexion Pharmaceuticals Boosts its Rare Disease Pipeline with Taligen Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 2 (Table of Contents)
Published: 14 Feb-2011
DOI: 10.3833/pdr.v2011.i2.1432 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to bolster its pipeline for rare diseases, Alexion Pharmaceuticals has purchased the privately held biotech company Taligen Therapeutics for US$111 M upfront and undisclosed contingent milestone payments for six of its drug programmes...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018